FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384695587> ?p ?o ?g. }

• W4384695587 endingPage "11547" @default.
• W4384695587 startingPage "11547" @default.
• W4384695587 abstract "In the past decade, targeted therapies for solid tumors, including non-small cell lung cancer (NSCLC), have advanced significantly, offering tailored treatment options for patients. However, individuals without targetable mutations pose a clinical challenge, as they may not respond to standard treatments like immune-checkpoint inhibitors (ICIs) and novel targeted therapies. While the mechanism of action of ICIs seems promising, the lack of a robust response limits their widespread use. Although the expression levels of programmed death ligand 1 (PD-L1) on tumor cells are used to predict ICI response, identifying new biomarkers, particularly those associated with the tumor microenvironment (TME), is crucial to address this unmet need. Recently, inflammatory cytokines such as interleukin-1 beta (IL-1β) have emerged as a key area of focus and hold significant potential implications for future clinical practice. Combinatorial approaches of IL-1β inhibitors and ICIs may provide a potential therapeutic modality for NSCLC patients without targetable mutations. Recent advancements in our understanding of the intricate relationship between inflammation and oncogenesis, particularly involving the IL-1β/PD-1/PD-L1 pathway, have shed light on their application in lung cancer development and clinical outcomes of patients. Targeting these pathways in cancers like NSCLC holds immense potential to revolutionize cancer treatment, particularly for patients lacking targetable genetic mutations. However, despite these promising prospects, there remain certain aspects of this pathway that require further investigation, particularly regarding treatment resistance. Therefore, the objective of this review is to delve into the role of IL-1β in NSCLC, its participation in inflammatory pathways, and its intricate crosstalk with the PD-1/PD-L1 pathway. Additionally, we aim to explore the potential of IL-1β as a therapeutic target for NSCLC treatment." @default.
• W4384695587 created "2023-07-20" @default.
• W4384695587 creator A5004510303 @default.
• W4384695587 creator A5005427020 @default.
• W4384695587 creator A5007069562 @default.
• W4384695587 creator A5007644298 @default.
• W4384695587 creator A5013435322 @default.
• W4384695587 creator A5032537689 @default.
• W4384695587 creator A5035539824 @default.
• W4384695587 creator A5042664406 @default.
• W4384695587 creator A5046336098 @default.
• W4384695587 creator A5046656928 @default.
• W4384695587 creator A5052756076 @default.
• W4384695587 creator A5066525575 @default.
• W4384695587 creator A5070441956 @default.
• W4384695587 creator A5087918194 @default.
• W4384695587 date "2023-07-17" @default.
• W4384695587 modified "2023-09-26" @default.
• W4384695587 title "Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical Management" @default.
• W4384695587 cites W1915043848 @default.
• W4384695587 cites W1985106893 @default.
• W4384695587 cites W2031153174 @default.
• W4384695587 cites W2044748328 @default.
• W4384695587 cites W2057073640 @default.
• W4384695587 cites W2058454017 @default.
• W4384695587 cites W2120929800 @default.
• W4384695587 cites W2135820395 @default.
• W4384695587 cites W2142160537 @default.
• W4384695587 cites W2184779060 @default.
• W4384695587 cites W2185075416 @default.
• W4384695587 cites W2201379305 @default.
• W4384695587 cites W2292383635 @default.
• W4384695587 cites W2400514548 @default.
• W4384695587 cites W2410977756 @default.
• W4384695587 cites W2421787307 @default.
• W4384695587 cites W2488061344 @default.
• W4384695587 cites W2527905628 @default.
• W4384695587 cites W2529393815 @default.
• W4384695587 cites W2548970662 @default.
• W4384695587 cites W2567564314 @default.
• W4384695587 cites W2586675028 @default.
• W4384695587 cites W2623388110 @default.
• W4384695587 cites W2737044461 @default.
• W4384695587 cites W2747774814 @default.
• W4384695587 cites W2749319028 @default.
• W4384695587 cites W2750254726 @default.
• W4384695587 cites W2753065806 @default.
• W4384695587 cites W2762777471 @default.
• W4384695587 cites W2772677509 @default.
• W4384695587 cites W2784371446 @default.
• W4384695587 cites W2789502254 @default.
• W4384695587 cites W2809059748 @default.
• W4384695587 cites W2902538632 @default.
• W4384695587 cites W2904125616 @default.
• W4384695587 cites W2912967789 @default.
• W4384695587 cites W2946386783 @default.
• W4384695587 cites W2954952837 @default.
• W4384695587 cites W2960815591 @default.
• W4384695587 cites W2965553739 @default.
• W4384695587 cites W2971246077 @default.
• W4384695587 cites W2987791246 @default.
• W4384695587 cites W2994567348 @default.
• W4384695587 cites W2997724502 @default.
• W4384695587 cites W2999401147 @default.
• W4384695587 cites W3000456443 @default.
• W4384695587 cites W3008707534 @default.
• W4384695587 cites W3015178699 @default.
• W4384695587 cites W3016210953 @default.
• W4384695587 cites W3017322331 @default.
• W4384695587 cites W3023067543 @default.
• W4384695587 cites W3026270374 @default.
• W4384695587 cites W3028144130 @default.
• W4384695587 cites W3029987135 @default.
• W4384695587 cites W3039320004 @default.
• W4384695587 cites W3039671381 @default.
• W4384695587 cites W3040716217 @default.
• W4384695587 cites W3043690500 @default.
• W4384695587 cites W3043942728 @default.
• W4384695587 cites W3049349821 @default.
• W4384695587 cites W3075660836 @default.
• W4384695587 cites W3082731516 @default.
• W4384695587 cites W3083801634 @default.
• W4384695587 cites W3089653221 @default.
• W4384695587 cites W3090467623 @default.
• W4384695587 cites W3092486443 @default.
• W4384695587 cites W3094924173 @default.
• W4384695587 cites W3095820231 @default.
• W4384695587 cites W3106005610 @default.
• W4384695587 cites W3106980882 @default.
• W4384695587 cites W3111497885 @default.
• W4384695587 cites W3117852629 @default.
• W4384695587 cites W3118950316 @default.
• W4384695587 cites W3129022890 @default.
• W4384695587 cites W3136699543 @default.
• W4384695587 cites W3139391091 @default.
• W4384695587 cites W3154805493 @default.
• W4384695587 cites W3165293110 @default.
• W4384695587 cites W3183409909 @default.

• next